CJC-1295 Without DAC (Mod GRF 1-29) in Mexico: physiological GH pulses

EXOMA Scientific Team · Publicado el 24 de mayo de 2026 · Actualizado el 18 de septiembre de 2026

Mod GRF (1-29) is the tetra-substituted version of the bioactive GHRH (1-29) fragment without the DAC linker. A half-life of ~30 minutes preserves the physiological pulsatility of GH.

Executive summary

CJC-1295 (Without DAC) (Modified GRF (1-29), CAS 863288-34-0, molecular formula C165H269N47O46, molecular weight 3647.99 g/mol) is the subject of growing interest in preclinical research owing to its short half-life (~30 min) that preserves the endogenous pulsatile pattern of GH. This technical guide brings together molecular characterization, mechanism of action, bibliographic evidence with DOI/PubMed, and handling considerations for research use only.

Regulatory notice. This material is exclusively for in vitro and preclinical research use. It does not constitute a clinical or therapeutic recommendation.

What is CJC-1295 (Without DAC)?

CJC-1295 Without DAC, also called Modified GRF (1-29) or Mod GRF 1-29, is a synthetic analog of the bioactive GHRH (1-29) fragment with four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that increase its stability against serum peptidases, without the albumin-binding DAC modification.

Key molecular data

Mechanism of action

Unlike the variant with DAC, its plasma half-life remains short (approximately 30 minutes), which preserves the circadian pattern and the frequency of physiological pulses of endogenous GH characteristic of the natural hypothalamic release.

The mechanistic characterization available in the indexed literature (PubMed, Web of Science) allows categorizing CJC-1295 (Without DAC) as an object of research of high interest in its category. The most cited publications are reproduced in the section Bibliographic evidence below.

Documented lines of research

The available preclinical literature addresses mainly:

1. Pharmacokinetic characterization: in vivo studies in murine and porcine models on absorption, distribution, metabolism, and excretion of the analog.
2. Receptor mechanisms: competitive binding assays with radioligands to map affinity and selectivity for target receptors.
3. Animal efficacy models: preclinical assays on the phenotypic effect attributable to the peptide in models of the pathology under study.
4. In vitro stability and formulation: evaluation of the chemical and biological stability of the peptide under different storage and reconstitution conditions.

For an up-to-date systematic review, the researcher is advised to consult the PubMed, Google Scholar and Web of Science databases using the terms CJC-1295 (Sin DAC) and Modified GRF (1-29).

Bibliographic evidence

• Alba M, Fintini D, Sagazio A, 2006 — Am J Physiol Endocrinol Metab. Daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH-knockout mouse. PubMed: 16822960
• Ionescu M, Frohman LA, 2006 — J Clin Endocrinol Metab. Pulsatile GH secretion persists under continuous stimulation with a long-acting GHRH analog, which supports the importance of the pulsatile pattern. PubMed: 17018654

Handling, reconstitution, and storage

Receipt and verification. Each lyophilized vial of CJC-1295 (No DAC) is shipped with its corresponding certificate of analysis (COA) issued by Chromasys, which includes identity by mass spectrometry, purity by reverse-phase HPLC, peptide content by amino acid analysis, residual acetate/TFA, residual water by Karl Fischer and endotoxins by LAL.

Standard reconstitution (research protocol). The standard procedure for sterile reconstitution is as follows:

1. Disinfect with isopropyl alcohol the rubber stoppers of the lyophilized CJC-1295 (No DAC) vial and of the vial of bacteriostatic water (BAC).
2. Aspirar el volumen calculado de BAC con jeringa de insulina estéril (consultar la EXOMA reconstitution calculator).
3. Inject the solvent slowly, resting the needle against the inner wall of the vial — never directly onto the lyophilized powder, to avoid aggregation and denaturation.
4. Gently roll the vial between your fingers until a clear solution is obtained. Never shake.
5. Store the reconstituted vial refrigerated (2–8 °C) protected from light. Avoid freeze-thaw cycles.

Storage of the lyophilizate. Refrigerated at 2–8 °C protected from light until the retest date indicated in the batch's COA.

Products available at EXOMA

• `/producto/cjc-1295-sindac`
• `/producto/cjc-1295-sindac`
• `/producto/cjc-1295-sindac`

All presentations are shipped with a batch COA and meet the reverse-phase HPLC purity standard. The larger-mass presentation usually offers the lowest cost per milligram.

Logistics and delivery

• Coverage. All of the Mexican Republic via courier with tracking number (AfterShip).
• Transit time. 1-4 business days depending on the region from payment confirmation.
• Shipping cost. $200 MXN de tarifa nacional única; envío gratuito en pedidos desde $2,000 MXN.
• Processing cutoff. Pedidos confirmados antes de las 16:30 (4:30 PM) hora del centro de México de lunes a viernes salen el mismo día hábil.

Additional resources

• Scientific hub: /producto/cjc-1295-sindac — variants, comparisons, studies, and full FAQ.
• Compendium: /compendio/cjc-1295-sindac — technical sheet with sequence and molecular references.
• Reconstitution calculator: /calculadora.
• Storage guide: /guia-conservacion.

This guide is educational content aimed at researchers. The information does not constitute medical advice or diagnosis. All data are reproduced for technical purposes and to support research-material procurement decisions. Bibliographic references are available on PubMed/DOI for independent verification.

References

Material for research use only. The following primary sources support the scientific claims of this article:

1. Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID 16352683.
2. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006. PMID 16822960. (estudio en ratón)